Reactivité: E. coli
EIA, Neut
Hôte: Souris
Monoclonal
557
unconjugated
Indications d'application
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Concentration
0.1 mg/mL
Buffer
PBS, 0.1 % bovine serum albumin
Stock
4 °C
Stockage commentaire
Product should be stored at 2-8 °C.
Antigène
VEROTOXIN
Sujet
Shiga-like toxins (SLTs), are also called Verotoxins. Enterohemorrhagic Escherichia coli (EHEC) strains which are primarily of serotypes 0157:H7, 026:H11, and O111:H8 have been incriminated as etiologic agents of hemorrhagic colitis and Hemolytic-uremic syndrome, a generalized disease characterized by acute renal failure, thrombocytopenia, and microangiopathic hemolytic anemia. There are several distinct E.coli SLTs. SLT-I and SLT-II are produced by EHEC. SLT-I and Shiga toxin share >99?% deduced amino acid sequence homology, whereas SLT-I and SLT-II share about 60?% deduced amino acid sequence homology. SLT-I and SLT-II are antigenically distinct. Antibodies to SLT-II can also neutralize a variant of SLT-II (designated SLT-Iiv) produced by strains of E.coli that cause edema. SLT-IIv is cytotoxic for Vero but not HeLa cells, distinguishing it from SLT-II. The protein structure of the toxin consists of two domains: the A polypeptide that inhibits protein synthesis by targeting ribosomes, and the B polypeptide pentamer that binds to the eukaryotic cell receptor globotriaosylceramide (Gb3) leading to receptor-mediated endocytosis.Synonyms: SLT-2 A subunit, SLT-2a, SLT-IIa, Verocytotoxin 2 subunit A, Verotoxin 2 subunit A, rRNA N-glycosidase 2, stx2A, stxA2